Steensen H, Lindqvist N
Allergy. 1981 May;36(4):245-9. doi: 10.1111/j.1398-9995.1981.tb01570.x.
The clinical effects of intranasal budesonide (16 alpha, 17 alpha (22 R,S) propylmethylenedioxypregana-1-4-diene-11beta 21 diol-3, 20 dione)) - a new non-halogenated glucocorticoid - were evaluated in a double-blind comparison with placebo, in patients with pronounced hay fever. Aerosolized budesonide, using a daily dosage of either 400 microgram or 200 microgram, showed a highly significantly reduction in the nasal symptoms as compared with placebo. No significant difference could be demonstrated between the effects of 400 microgram and 200 microgram per day, suggesting that the lower dosage is adequate. No significant effect on the eye symptoms and no fall in plasma cortisol values were observed with either dosage. Only mild side effects were reported.
在一项针对重度花粉热患者的双盲研究中，将新型非卤化糖皮质激素鼻用布地奈德（16α,17α(22R,S)-亚丙基二氧孕甾-1,4-二烯-11β,21-二醇-3,20-二酮）与安慰剂进行了比较，以评估其临床疗效。每日使用400微克或200微克雾化布地奈德的患者，与使用安慰剂的患者相比，鼻部症状有极显著减轻。每天400微克和200微克剂量的效果之间未显示出显著差异，这表明较低剂量就足够了。两种剂量均未观察到对眼部症状有显著影响，也未观察到血浆皮质醇值下降。仅报告了轻微的副作用。
